Realyze Intelligence is honored to announce that they have been selected by the Creative Destruction Lab (CDL) to join their current cancer program cohort. This unique joint venture between CDL and the Canadian Cancer Society (CCS) aims to improve the global cancer experience.
The Creative Destruction Lab offers a proverbial space for the world’s most-promising, massively scalable, science- and technology-based companies to “create something massive” with the ultimate goal to “enhance the commercialization of science for the betterment of humankind”. Inside the lab start-up founders can leverage mentorship, technical expertise and network acceleration to home in on the highest priority tasks to massively scale their innovative products.
Realyze Intelligence was competitively selected to join an exclusive 9-month acceleration program. This unique opportunity offers exposure to “global leaders and experts across the cancer care continuum [who] support technology innovations that improve the cancer experience globally, from prevention to diagnosis, treatment, and survivorship.”
“Our team is honored and excited to be a part of CDL-Cancer. We are passionate about our mission to improve cancer care by accelerating clinical trials and delivering real world data and confident that the CDL-Cancer program and the community surrounding it will aid us in achieving our mission,” said Aaron Brauser, Founder, President, and CEO of Realyze Intelligence.
Realyze Intelligence will be actively engaged with CDL-Cancer from October 2023 through May 2024.